<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6119173/results/search/disease/results.xml">
  <result pre="Effect of exogenous estrogens and progestogens on the course of" exact="migraine" post="during reproductive age: a consensus statement by the European"/>
  <result pre="effect of exogenous estrogens and progestogens on the course of" exact="migraine" post="during reproductive age. Thereafter a consensus procedure among international"/>
  <result pre="support clinical decision making, in terms of possible effects on" exact="migraine" post="course of exogenous estrogens and progestogens and on possible"/>
  <result pre="Introduction The role of female hormones in the pathogenesis of" exact="migraine" post="is well-recognized [ 1, 2]. Migraine is more prevalent"/>
  <result pre="menstrual phase of the female cycle represents a trigger for" exact="migraine" post="attacks in many women [ 1, 4]. Additionally, exogenous"/>
  <result pre="1, 4]. Additionally, exogenous hormones may change the course of" exact="migraine" post="by inducing de novo migraine, inducing de novo aura,"/>
  <result pre="inducing de novo migraine, inducing de novo aura, worsening previous" exact="migraine" post="but also improving migraine particularly those attacks related to"/>
  <result pre="inducing de novo aura, worsening previous migraine but also improving" exact="migraine" post="particularly those attacks related to menstruation [ 5, 6]."/>
  <result pre="related to menstruation [ 5, 6]. The criteria to diagnose" exact="migraine" post="related to menstruation (Table 1) and to diagnose headache"/>
  <result pre="Disorders (ICHD), 1988, did not report any formal criteria for" exact="migraine" post="related to menstruation [ 7]. The authors recognized that"/>
  <result pre="menstruation [ 7]. The authors recognized that in some women," exact="migraine" post="without aura (MO) may be almost exclusively linked with"/>
  <result pre="may be almost exclusively linked with menstruation, so called menstrual" exact="migraine" post="(MM), and indicated that it seemed reasonable to require"/>
  <result pre="menses and the last day of menses. Appendix criteria for" exact="migraine" post="related to menstruation were introduced in 2004, with the"/>
  <result pre="(Table 1) [ 8]. Two entities were recognised: pure menstrual" exact="migraine" post="(PMM) where attacks are exclusively related to menstruation; menstrually"/>
  <result pre="(PMM) where attacks are exclusively related to menstruation; menstrually related" exact="migraine" post="(MRM) where attacks occur additionally at other times of"/>
  <result pre="Both were forms of MO, along with non-menstrual MO or" exact="migraine" post="with aura (MA) in the case of MRM. PMM"/>
  <result pre="available since 2018 [ 10]. Table 1 Diagnostic criteria of" exact="migraine" post="related to menstruation according to the different editions of"/>
  <result pre="Headache Disorders (ICHD) ICHD, II edition, 2004  A.1.1.1 Pure menstrual" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="and at no other times of the cycle  A.1.1.2 Menstrually-related" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="cycle ICHD, III edition, beta version, 2013  A1.1.1 Pure menstrual" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="at no other times of the cycle  A1.1.2 Menstrually related" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="of the cycle ICHD, III edition, 2018  A1.1.1 Pure menstrual" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="at no other times of the cycle  A1.1.2 Menstrually related" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="additionally at other times of the cycle  A1.2.0.1 Pure menstrual" exact="migraine" post="with aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="at no other times of the cycle  A1.2.0.2 Menstrually related" exact="migraine" post="with aura   A. Attacks, in a menstruating woman, fulfilling"/>
  <result pre="II edition, 2004  8.3.1 Exogenous hormone-induced headache   A. Headache or" exact="migraine" post="fulfilling criteria C and D   B. Regular use of"/>
  <result pre="D   B. Regular use of exogenous hormones   C. Headache or" exact="migraine" post="develops or markedly worsens within 3 months of commencing"/>
  <result pre="within 3 months of commencing exogenous hormones   D. Headache or" exact="migraine" post="resolves or reverts to its previous pattern within 3"/>
  <result pre="discontinuation of exogenous hormones  8.4.3 Estrogen-withdrawal headache   A. Headache or" exact="migraine" post="fulfilling criteria C and D   B. Daily use of"/>
  <result pre="estrogen for ≥3 weeks, which is interrupted   C. Headache or" exact="migraine" post="develops within 5 days after last use of estrogen"/>
  <result pre="5 days after last use of estrogen   D. Headache or" exact="migraine" post="resolves within 3 days ICHD, III edition, beta version,"/>
  <result pre="by another ICHD-3 diagnosis  8.3.3 Estrogen-withdrawal headache   A. Headache or" exact="migraine" post="fulfilling criterion C   B. Daily use of exogenous estrogen"/>
  <result pre="causation demonstrated by both of the following:     1. headache or" exact="migraine" post="has developed within five days after the last use"/>
  <result pre="days after the last use of estrogen     2. headache or" exact="migraine" post="has resolved within three days of its onset   D."/>
  <result pre="by another ICHD-3 diagnosis  8.3.3 Estrogen-withdrawal headache   A. Headache or" exact="migraine" post="fulfilling criterion C   B. Daily use of exogenous estrogen"/>
  <result pre="causation demonstrated by both of the following:     1. headache or" exact="migraine" post="has developed within five days after the last use"/>
  <result pre="days after the last use of estrogen     2. headache or" exact="migraine" post="has resolved within three days of its onset   D."/>
  <result pre="to manipulate the female hormonal cycle to try to improve" exact="migraine" post="[ 6, 11]. Studies have investigated both MO, MA"/>
  <result pre="[ 6, 11]. Studies have investigated both MO, MA and" exact="migraine" post="attacks related to menstruation [ 6, 11]. Additionally, as"/>
  <result pre="11]. Additionally, as in users of combined hormonal contraceptives (CHC)" exact="migraine" post="attacks mostly occur during the hormone free interval, studies"/>
  <result pre="different estrogen or progestogen regimens impact on the course of" exact="migraine" post="[ 12– 15]. CHC have been associated with an"/>
  <result pre="CHC have been associated with an increased risk of ischemic" exact="stroke" post="in women with migraine [ 16– 21]. A working"/>
  <result pre="with an increased risk of ischemic stroke in women with" exact="migraine" post="[ 16– 21]. A working group including headache experts,"/>
  <result pre="[ 16– 21]. A working group including headache experts, gynaecologists," exact="stroke" post="experts, and epidemiologists developed a first consensus document about"/>
  <result pre="consensus document is to provide recommendations on the management of" exact="migraine" post="with the use of estrogens and progestogens in women"/>
  <result pre="EHF representatives selected a panel of international multidisciplinary experts in" exact="migraine" post="and hormonal contraception (HC). The panel was chosen to"/>
  <result pre="guidance to clinicians about evidence-based options for the management of" exact="migraine" post="with exogenous estrogens and progestogens. Review of the literature"/>
  <result pre="study period, number of included patients, diagnostic criteria for migraine," exact="migraine" post="type, treatments type, duration of observations and treatments, study"/>
  <result pre="of estrogen or progestogen; 5) reporting any outcome referring to" exact="migraine" post="frequency, severity, duration, disability, or use of drugs to"/>
  <result pre="headache [ 15, 40]. Drugs which were evaluated to manage" exact="migraine" post="in women of reproductive age include the desogestrel progestogen-only"/>
  <result pre="headache intensity, days with headache score 3, analgesic use Reduced" exact="migraine" post="days, headache intensity, days with headache and use of"/>
  <result pre="neurological symptoms or associated symptoms, analgesic use Reduced number of" exact="migraine" post="attacks in previous COCs users and nonusers Desogestrel progestogen-only"/>
  <result pre="score 3, pain medication, triptan use, quality of life Reduced" exact="migraine" post="days, headache days pain intensity, number of days with"/>
  <result pre="treatment (pre-treatment observation period not-defined) Severity, number and duration of" exact="migraine" post="attacks, associated symptoms Decreased number and intensity of migraine"/>
  <result pre="of migraine attacks, associated symptoms Decreased number and intensity of" exact="migraine" post="attacks in POP users Extended regimen of combined oral"/>
  <result pre="phenomena, analgesic use Reduction in the number and duration of" exact="migraine" post="attacks, in hours of severe pain, and in use"/>
  <result pre="days of migraine; severity of migraine; number of days of" exact="migraine" post="with associated symptoms Trend towards reducing the frequency and"/>
  <result pre="associated symptoms Trend towards reducing the frequency and severity of" exact="migraine" post="with the patch Combined hormonal contraceptive patch  LaGuardia, 2005"/>
  <result pre="1986 [ 31] Randomized, placebo-controlled, double-blind, crossover MM (No ICHD;" exact="migraine" post="without aura occurring exclusively not earlier than 2 days"/>
  <result pre="of treatment, 27 cycles of placebo Occurrence, duration, severity of" exact="migraine" post="attacks, aspirin use Reduction in the occurrence and severity"/>
  <result pre="[ 32] Randomized, placebo-controlled, double-blind, crossover MM (No ICHD; regular" exact="migraine" post="in the paramenstruum); women specifically treated for headache 22;"/>
  <result pre="attacks, associated symptoms, occurrence of aura, analgesic use Reduction in" exact="migraine" post="days and attacks severity; increase in migraine occurrence in"/>
  <result pre="use Reduction in migraine days and attacks severity; increase in" exact="migraine" post="occurrence in the 5 days immediately after estradiol use"/>
  <result pre="3 cycles for active treatment Number, severity and intensity of" exact="migraine" post="attacks No differences between active treatment and placebo  Guidotti,"/>
  <result pre="treatment (6 days before expected menstruation) Number and severity of" exact="migraine" post="attacks Reduction in number of migraine attacks and severity"/>
  <result pre="Number and severity of migraine attacks Reduction in number of" exact="migraine" post="attacks and severity of attacks with frovatriptan than with"/>
  <result pre="for 3 cycles (estradiol-placebo-estradiol or placebo-estradiol-placebo) Presence, duration, severity of" exact="migraine" post="attacks, analgesic use No differences between active treatment and"/>
  <result pre="month 2.5 years (mean duration) of treatment Improvement of menstrual" exact="migraine" post="95.8% of patients with improvement in MM; 46% became"/>
  <result pre="became headache-free and 37.5% gained almost complete symptomatic relief MO" exact="migraine" post="without aura, MA migraine with aura, ICHD International Classification"/>
  <result pre="gained almost complete symptomatic relief MO migraine without aura, MA" exact="migraine" post="with aura, ICHD International Classification of Headache Disorders, EE"/>
  <result pre="PMM pure menstrual migraine, MRM menstrually related migraine, MM menstrual" exact="migraine" post="Table 4 Assessment for rating up the quality of"/>
  <result pre="Treatment with desogestrel was associated with a significant reduction in" exact="migraine" post="days (6.2 ± 4.2 vs 5.2 ± 5.3; P = 0.001"/>
  <result pre="The authors found a significant reduction in the number of" exact="migraine" post="attacks ( P &amp;lt; 0.001) and of aura symptoms ( P &amp;lt; 0.02)"/>
  <result pre="pain and on analgesic consumption. Benefits in the reduction of" exact="migraine" post="attacks were evident in both users (3.9 ± 1.0 vs 2.9 ± 0.8;"/>
  <result pre="that treatment with desogestrel was associated with a reduction in" exact="migraine" post="days per month (5.5 ± 2.6 vs 3.5 ± 1.2; P &amp;lt; 0.001), headache days"/>
  <result pre="vs 4.9 ± 1.7; P = 0.005), and duration (20.5 ± 7.9 vs 15.9 ± 4.4; P &amp;lt; 0.001) of" exact="migraine" post="attacks. Side effects associated with desogestrel use included higher"/>
  <result pre="treatment with oral desogestrel may be associated with improvement in" exact="migraine" post="in women with MO and MA. However, treatment has"/>
  <result pre="of estrogens and progestogens in women of reproductive age with" exact="migraine" post="considering their effect on migraine course Treatment Population Recommendation"/>
  <result pre="women of reproductive age with migraine considering their effect on" exact="migraine" post="course Treatment Population Recommendation Quality of Evidence Strength of"/>
  <result pre="combined contraceptive regimen with oral pill or patch* Women with" exact="migraine" post="who require hormonal contraception Not suggested None Weak Alternative"/>
  <result pre="usual headache with combined hormonal contraceptives; women with new onset" exact="migraine" post="with combined hormonal contraceptives Suggested None Weak Women with"/>
  <result pre="None Weak Women with migraine, related to menstruation, who require" exact="migraine" post="preventive treatments and who have contraindication or failure of"/>
  <result pre="Women with migraine, related to menstruation, who have not tried" exact="migraine" post="preventive drugs and who have no need of desogestrel-only"/>
  <result pre="of pill or patch) of combined contraceptives for women with" exact="migraine" post="Extended regimens of the contraceptive patch may be preferable"/>
  <result pre="None Weak Women with migraine, related to menstruation, who require" exact="migraine" post="preventive treatments and who have contraindication or failure of"/>
  <result pre="Women with migraine, related to menstruation, who have not tried" exact="migraine" post="preventive drugs and who have no need of desogestrel-only"/>
  <result pre="Transdermal estradiol supplementation with estradiol gel Women with pure menstrual" exact="migraine" post="Suggested Low Weak Patients should be informed that delayed"/>
  <result pre="migraine Suggested Low Weak Patients should be informed that delayed" exact="migraine" post="may occur and that treatment is potentially effective only"/>
  <result pre="effective only on attacks related to menstruation Women with menstrually-related" exact="migraine" post="Suggested Low Weak Women with estrogen-withdrawal headache Suggested None"/>
  <result pre="Weak Transdermal estradiol supplementation with patch Women with pure menstrual" exact="migraine" post="Not suggested Low Weak Women with menstrually-related migraine Not"/>
  <result pre="pure menstrual migraine Not suggested Low Weak Women with menstrually-related" exact="migraine" post="Not suggested Low Weak Women with estrogen-withdrawal headache Not"/>
  <result pre="with patch in women induced in pharmacological menopause Women with" exact="migraine" post="Not suggested Low Weak Subcutaneous estradiol; implant and cyclical"/>
  <result pre="Subcutaneous estradiol; implant and cyclical progestogen Women with pure menstrual" exact="migraine" post="Not suggested Low Weak Women with menstrually-related migraine Not"/>
  <result pre="pure menstrual migraine Not suggested Low Weak Women with menstrually-related" exact="migraine" post="Not suggested Low Weak *According to the Consensus Statement"/>
  <result pre="migraine, compounds containing estrogens are not suggested for women with" exact="migraine" post="with aura and for women with migraine without aura"/>
  <result pre="for women with migraine with aura and for women with" exact="migraine" post="without aura and additional vascular risk factors [ 22]"/>
  <result pre="contraceptive was associated with a reduction in the duration of" exact="migraine" post="attacks (22.7 ± 9.0 vs 18.9 ± 6.0; P = 0.007) but not in reduction"/>
  <result pre="the use of extended oral CHCs regimens in women with" exact="migraine" post="is limited as it comes from observational studies performed"/>
  <result pre="P = 0.044). There was no difference between the two group in" exact="migraine" post="days, headache days, headache intensity, days with headache score"/>
  <result pre="were associated with reduction in headache intensity and days of" exact="migraine" post="as compared to baseline observation. Treatment with the shortened"/>
  <result pre="least 3 months before enrollment. After treatment, the number of" exact="migraine" post="attack days was reduced from 2.7 ± 0.9 days at baseline"/>
  <result pre="of oral CHCs with shortened pill-free interval in women with" exact="migraine" post="is limited. Available studies included PMM or MRM. One"/>
  <result pre="but it is important to note that some women with" exact="migraine" post="may be particularly sensitive to hormonal administration and need"/>
  <result pre="related to treatment or rather to natural fluctuations in the" exact="migraine" post="course nor it is clear if improvements can be"/>
  <result pre="in women with MO associated with menstruation and women with" exact="migraine" post="associated with CHC withdrawal bleeding [ 44]. The study"/>
  <result pre="oral estrogen supplementation during the pill-free interval in women with" exact="migraine" post="is limited to a single unreliable study. Recommendations for"/>
  <result pre="benefits of transdermal estradiol supplementation with patch in women with" exact="migraine" post="during the pill-free interval of combined oral contraceptives ["/>
  <result pre="days of migraine, severity of migraine, number of days with" exact="migraine" post="with associated symptoms. Adverse events related to transdermal estradiol"/>
  <result pre="study show no benefit of estradiol supplementation with patches on" exact="migraine" post="occurrence during the pill-free interval, this cannot be considered"/>
  <result pre="conclusion, data referring to the effect of CHC patch on" exact="migraine" post="are very limited. One study only evaluated the effect"/>
  <result pre="not defined and authors did not provide any information about" exact="migraine" post="frequency, severity or disability before and after treatments. The"/>
  <result pre="on the use of CHC vaginal ring in women with" exact="migraine" post="is very limited. There are not enough data to"/>
  <result pre="concerns over a possible increase in the risk of ischemic" exact="stroke" post="[ 22]. No ischemic strokes were reported during the"/>
  <result pre="less use of aspirin. One out of 20 patients had" exact="migraine" post="three days after stopping estradiol treatment. Dennerstein et al."/>
  <result pre="significant difference in the occurrence of moderate to severe intensity" exact="migraine" post="during the months of treatment with percutaneous estradiol compared"/>
  <result pre="authors considered that treatment would not be expected to affect" exact="migraine" post="which occurred prior to or after the use of"/>
  <result pre="according to ICHD-2 criteria. The authors reported a reduction in" exact="migraine" post="days and attack severity. Estradiol was associated with a"/>
  <result pre="attack severity. Estradiol was associated with a 22% reduction in" exact="migraine" post="days per woman (relative risk [RR] 0.78; 95% CI"/>
  <result pre="significant. However, in this study authors found an increase in" exact="migraine" post="occurrence in the 5 days immediately following estradiol use"/>
  <result pre="had fewer migraines compared to using placebo), 15 experienced post-gel" exact="migraine" post="(they had more migraine days during the 5 days"/>
  <result pre="to using placebo), 15 experienced post-gel migraine (they had more" exact="migraine" post="days during the 5 days after the estradiol gel"/>
  <result pre="use of transdermal estradiol supplementation with gel in women with" exact="migraine" post="is limited. Transdermal estradiol supplementation with gel is easy"/>
  <result pre="life. Possible benefits may be offset by an increase in" exact="migraine" post="following gel use, associated with an iatrogenic delayed estrogen"/>
  <result pre="withdrawal. Possible reasons for the occurrence of post-gel estrogen withdrawal" exact="migraine" post="are that the dose of estradiol was inadequate; the"/>
  <result pre="or are not feasible. Women should be aware that delayed" exact="migraine" post="may occur and in those circumstances treatment should be"/>
  <result pre="not find any benefit in number, severity, and intensity of" exact="migraine" post="attacks. Guidotti et al. performed an observational, prospective, parallel"/>
  <result pre="single cycle. Authors reported that frovatriptan was associated with reduced" exact="migraine" post="incidence and severity while they did not report benefits"/>
  <result pre="not find any difference in presence, duration, and severity of" exact="migraine" post="attacks and in the use of analgesics between active"/>
  <result pre="the time of the anticipated start of the bleeding and" exact="migraine" post="attacks, dosing and timing of treatment are very important."/>
  <result pre="clinical benefits whereas higher doses may increase risk of ischemic" exact="stroke" post="[ 33]. Also, duration of estradiol supplementation may impact"/>
  <result pre="no data showing benefits of estradiol supplementation with patches on" exact="migraine" post="occurrence, this cannot be considered as a possible therapeutic"/>
  <result pre="wall. Patients were included in this study specifically to treat" exact="migraine" post="after failure of previous treatments. Mean duration of treatment"/>
  <result pre="not defined and authors did not provide any information about" exact="migraine" post="frequency, severity or disability before and after treatment. No"/>
  <result pre="all but one patient noted an improvement in their menstrual" exact="migraine" post="following treatment. Eleven (46%) became completely headache-free and nine"/>
  <result pre="progestogens in women of reproductive age and their effect on" exact="migraine" post="is limited. All the recommendations were based on low"/>
  <result pre="is the option which may offer more evident benefit on" exact="migraine" post="course. From a cardiovascular point of view in women"/>
  <result pre="course. From a cardiovascular point of view in women with" exact="migraine" post="it is also the safest form [ 22, 46]."/>
  <result pre="safest form [ 22, 46]. The desogestrel pill may improve" exact="migraine" post="frequency and severity in women with MA or MO"/>
  <result pre="this drug as a specific therapeutic option for women with" exact="migraine" post="is available. It is important to note that in"/>
  <result pre="note that in some patient the desogestrel pill may worsen" exact="migraine" post="or may be associated with new onset migraine. Unfavorable"/>
  <result pre="estrogen withdrawal headache, particularly those women already experiencing headache or" exact="migraine" post="during the pill-free interval. Less certain is the option"/>
  <result pre="this contraceptive method is associated with de novo occurrence of" exact="migraine" post="or migraine worsening in a substantial proportion of female"/>
  <result pre="method is associated with de novo occurrence of migraine or" exact="migraine" post="worsening in a substantial proportion of female migraineurs, although"/>
  <result pre="interval [ 47– 50]. It is important to note that" exact="migraine" post="may improve in some patients with the use of"/>
  <result pre="no tools or clinical features to predict the course of" exact="migraine" post="after oral CHC initiation. In women who have menstrual"/>
  <result pre="oral CHC initiation. In women who have menstrual attacks of" exact="migraine" post="during natural cycles, a therapeutic option may the administration"/>
  <result pre="evidence-based and expert-agreed guidance to clinicians for the management of" exact="migraine" post="with exogenous estrogens and progestogens. The available evidence is"/>
  <result pre="whether the treatments discussed may be specifically applied to treat" exact="migraine" post="in selected women. Abbreviations CHC Combined hormonal contraceptives CI"/>
  <result pre="Classification of Headache Disorders MA Migraine with aura MM Menstrual" exact="migraine" post="MO Migraine without aura MRM Menstrually related migraine PHC"/>
  <result pre="MM Menstrual migraine MO Migraine without aura MRM Menstrually related" exact="migraine" post="PHC Progestogen-only hormonal contraceptive PMM Pure menstrual migraine POP"/>
  <result pre="Menstrually related migraine PHC Progestogen-only hormonal contraceptive PMM Pure menstrual" exact="migraine" post="POP Progestogen-only pill RR Relative risk SE Standard error"/>
  <result pre="affiliations. References References 1. MacGregor EA Oestrogen and attacks of" exact="migraine" post="with and without aura Lancet Neurol 2014 3 354"/>
  <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol 2017 16 76 87 10.1016/S1474-4422(16)30293-9 27836433 3."/>
  <result pre="Garrick R Tomlinson SE Effectiveness of the progestin-only pill for" exact="migraine" post="treatment in women: a systematic review and meta-analysis Cephalalgia"/>
  <result pre="10.1177/0333102417738202 29368949 11. MacGregor EA Prevention and treatment of menstrual" exact="migraine" post="Drugs 2010 70 1799 1818 10.2165/11538090-000000000-00000 20836574 12. Martin"/>
  <result pre="with and without estrogen add-back therapy in the prevention of" exact="migraine" post="headache Headache 2003 43 309 321 10.1046/j.1526-4610.2003.03065.x 12656701 13."/>
  <result pre="oral contraceptive in the treatment of pain symptoms caused by" exact="endometriosis" post="in patients with migraine without aura Eur J Obstet"/>
  <result pre="treatment of pain symptoms caused by endometriosis in patients with" exact="migraine" post="without aura Eur J Obstet Gynecol Reprod Biol 2014"/>
  <result pre="contraception compared with extended combined oral contraceptive in women with" exact="migraine" post="without aura: a retrospective pilot study Eur J Obstet"/>
  <result pre="16. Carolei A Marini C De Matteis G History of" exact="migraine" post="and risk of cerebral ischaemia in young adults The"/>
  <result pre="young adults The Italian National Research Council study group on" exact="stroke" post="in the young Lancet 1996 347 1503 1506 17."/>
  <result pre="hormonal contraceptives among women with migraines and risk of ischemic" exact="stroke" post="Am J Obstet Gynecol 2017 216 489.e1 489.e7 10.1016/j.ajog.2016.12.019"/>
  <result pre="28034652 18. Chang CL Donaghy M Poulter N Migraine and" exact="stroke" post="in young women: case–control study. The World Health Organization"/>
  <result pre="women: case–control study. The World Health Organization collaborative study of" exact="cardiovascular disease" post="and steroid hormone contraception BMJ 1999 318 13 18"/>
  <result pre="J Wozniak M Stern B Mitchell BD Kittner SJ Probable" exact="migraine" post="with visual aura and risk of ischemic stroke: the"/>
  <result pre="migraine with visual aura and risk of ischemic stroke: the" exact="stroke" post="prevention in young women study Stroke 2007 38 2438"/>
  <result pre="21. Sacco S Kurth T Migraine and the risk of" exact="stroke" post="and cardiovascular disease Curr Cardiol Rep 2014 16 524"/>
  <result pre="S Kurth T Migraine and the risk of stroke and" exact="cardiovascular disease" post="Curr Cardiol Rep 2014 16 524 10.1007/s11886-014-0524-1 25059466 22."/>
  <result pre="Contraception and Reproductive Health (ESC) HCs and risk of ischemic" exact="stroke" post="in women with migraine: a consensus statement from the"/>
  <result pre="M Lindh-Åstrand L Landtblom AM Brynhildsen J Prevention of menstrual" exact="migraine" post="with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover"/>
  <result pre="P Mas JL Touboul PJ Bousser MG Prevention of menstrual" exact="migraine" post="by percutaneous estradiol Br Med J 1986 293 1540"/>
  <result pre="transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual" exact="migraine" post="J Heachache Pain 2007 8 283 288 10.1007/s10194-007-0417-4 34."/>
  <result pre="283 288 10.1007/s10194-007-0417-4 34. MacGregor EA Hackshaw A Prevention of" exact="migraine" post="in the pill-free interval of combined oral contraceptives: a"/>
  <result pre="36. Magos A Zilkha KJ Studd JW Treatment of menstrual" exact="migraine" post="by oestradiol implants JNNP 1983 46 1044 1046 37."/>
  <result pre="Correlation between estradiol plasma level and therapeutic effect on menstrual" exact="migraine" post="New advances in headache research 1994 London Smith-Gordon 129"/>
  <result pre="the value of contingent negative variation and exteroceptive temporalis muscle" exact="suppression" post="test Headache 1993 34 103 106 10.1111/j.1526-4610.1994.hed3402103.x 39. De"/>
  <result pre="G Cianci A Combined oral contraceptives in women with menstrual" exact="migraine" post="without aura Fertil Steril 2011 96 917 920 10.1016/j.fertnstert.2011.07.1089"/>
  <result pre="Imthurn B Dubey R Sándor PS Gantenbein AR Improvement of" exact="migraine" post="with change from combined hormonal contraceptives to progestin-only contraception"/>
  <result pre="of an estrogen-free, desogestrel containing oral contraceptive in women with" exact="migraine" post="with aura: a prospective diary-based pilot study Contraception 2011"/>
  <result pre="containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related" exact="migraine" post="(MRM) Contraception 2013 88 369 375 10.1016/j.contraception.2013.02.001 23453784 44."/>
  <result pre="23453784 44. Calhoun AH A novel specific prophylaxis for menstrual-associated" exact="migraine" post="South Med J 2004 97 819 822 10.1097/01.SMJ.0000129924.15619.D9 15455962"/>
  <result pre="Pruitt A The impact of extended-cycle vaginal ring contraception on" exact="migraine" post="aura: a retrospective case series Headache 2012 52 1246"/>
  <result pre="Martins L, Luminoso D (2010) Epidemiological and clinical aspects of" exact="migraine" post="in users of combined oral contraceptives. Contraception 81:202–208"/>
 </snippets>
</snippetsTree>
